Literature DB >> 29239350

Suppression of eEF-2K-mediated autophagy enhances the cytotoxicity of raddeanin A against human breast cancer cells in vitro.

Yi-di Guan1, Shi-Long Jiang1, Pian Yu1, Mei Wen1, Yi Zhang2, Song-Shu Xiao3, Xiao-Jun Xu4, Yan Cheng1.   

Abstract

Recent evidence shows that raddeanin A (RA), an oleanane-type triterpenoid saponin extracted from Anemone raddeana Regel, exerts remarkable cytotoxicity against cancer cells in vitro and in vivo. In addition, RA has also been found to activate autophagy in human gastric cancer cells. In this study, we investigated the molecular mechanisms underlying RA-induced autophagy as well as the relationship between RA-induced autophagy and its cytotoxicity in human breast cancer cells in vitro. Treatment with RA (2-8 μmol/L) dose-dependently enhanced autophagy, as evidenced by increased LC3 levels in breast cancer cell lines T47D, MCF-7 and MDA-MB-231. Furthermore, the Akt-mTOR-eEF-2K signaling pathway was demonstrated to be involved in RA-induced activation of autophagy in the 3 breast cancer cell lines. Treatment with RA (2-10 μmol/L) dose-dependently induced apoptosis in the 3 breast cancer cell lines. Pretreatment with the autophagy inhibitor chloroquine (CQ, 20 μmol/L) significantly enhanced RA-caused cytotoxicity via promoting apoptosis. In conclusion, our results suggest that modulating autophagy can reinforce the cytotoxicity of RA against human breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29239350      PMCID: PMC5888684          DOI: 10.1038/aps.2017.139

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  23 in total

1.  Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization.

Authors:  M A Qadir; B Kwok; W H Dragowska; K H To; D Le; M B Bally; Sharon M Gorski
Journal:  Breast Cancer Res Treat       Date:  2008-01-03       Impact factor: 4.872

2.  Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.

Authors:  L L Fu; T Xie; S Y Zhang; B Liu
Journal:  Apoptosis       Date:  2014-10       Impact factor: 4.677

Review 3.  Targeting autophagy in cancer stem cells as an anticancer therapy.

Authors:  Yuanyuan Lei; Dan Zhang; Jin Yu; Hui Dong; Jianwei Zhang; Shiming Yang
Journal:  Cancer Lett       Date:  2017-02-17       Impact factor: 8.679

4.  Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.

Authors:  Yan Cheng; Huaijun Li; Xingcong Ren; Tingkuang Niu; William N Hait; Jinming Yang
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

5.  Elongation factor-2 kinase regulates autophagy in human glioblastoma cells.

Authors:  Hao Wu; Jin-Ming Yang; Shengkan Jin; Haiyan Zhang; William N Hait
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

6.  [Antitumor effects of raddeanin A on S180, H22 and U14 cell xenografts in mice].

Authors:  Ming-Kui Wang; Li-Sheng Ding; Feng-E Wu
Journal:  Ai Zheng       Date:  2008-09

7.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.

Authors:  Diane C Fingar; Sofie Salama; Christina Tsou; Ed Harlow; John Blenis
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

Review 8.  Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.

Authors:  Justin W Kenney; Claire E Moore; Xuemin Wang; Christopher G Proud
Journal:  Adv Biol Regul       Date:  2014-04-30

9.  Autophagy Protects from Raddeanin A-Induced Apoptosis in SGC-7901 Human Gastric Cancer Cells.

Authors:  Yu-Hao Teng; Jie-Pin Li; Shen-Lin Liu; Xi Zou; Liang-Hua Fang; Jin-Yong Zhou; Jian Wu; Song-Yang Xi; Yan Chen; Ying-Ying Zhang; Song Xu; Rui-Ping Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-15       Impact factor: 2.629

10.  Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.

Authors:  Guilhem Bousquet; Morad El Bouchtaoui; Tan Sophie; Christophe Leboeuf; Cédric de Bazelaire; Philippe Ratajczak; Sylvie Giacchetti; Anne de Roquancourt; Philippe Bertheau; Laurence Verneuil; Jean-Paul Feugeas; Marc Espié; Anne Janin
Journal:  Oncotarget       Date:  2017-05-23
View more
  4 in total

1.  Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro.

Authors:  Pian Yu; Hai-Yan Wang; Min Tian; Ao-Xue Li; Xi-Sha Chen; Xin-Luan Wang; Yi Zhang; Yan Cheng
Journal:  Acta Pharmacol Sin       Date:  2019-03-26       Impact factor: 6.150

2.  Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer.

Authors:  Hongyan Xia; Cheng Hu; Shanshan Bai; Jing Lyu; Bryan Y Zhang; Xianghui Yu; Yang Zhan; Lijing Zhao; Yan Dong
Journal:  J Cell Mol Med       Date:  2019-03-23       Impact factor: 5.310

3.  1α,25(OH)2D3(VD3) promotes Raddeanin A-induced anti-proliferative effects on HeLa cell apoptosis and autophagy through negative regulation of HPV18E6-E7/PD-L1/VDR axis.

Authors:  Zhiyu Li; Biyun Xu; Yuexin Sun; Lanbo Zhou; Yue Tao; Wenjun Hou; Jun Bao; Jun Liu; Weixin Fan
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

4.  eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.

Authors:  Xisha Chen; Kuansong Wang; Shilong Jiang; Hongyin Sun; Xuanling Che; Minghui Zhang; Jiaying He; Ying Wen; Mengting Liao; Xiangling Li; Xiaoming Zhou; Jianxun Song; Xingcong Ren; Wenjun Yi; Jinming Yang; Xiang Chen; Mingzhu Yin; Yan Cheng
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.